{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:57:26Z","timestamp":1794049046405,"version":"4.8.0"},"reference-count":30,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,10,19]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. We aimed to perform a systematic review and Bayesian meta-analysis of randomised CEP trials, focusing on a clinically relevant reduction in disabling stroke.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic search was applied to three electronic databases, including trials that randomised TAVI patients to CEP versus standard treatment. The primary outcome was the risk of disabling stroke. Outcomes were presented as relative risk (RR), absolute risk differences (ARDs), numbers needed to treat (NNTs) and the 95% credible intervals (CrIs). The minimal clinically important difference was determined at 1.1% ARD, per expert consensus (NNT 91). The principal Bayesian meta-analysis was performed under a vague prior, and secondary analyses were performed under two informed literature-based priors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven randomised studies were included for meta-analysis (n=3996: CEP n=2126, control n=1870). Under a vague prior, the estimated median RR of CEP use for disabling stroke was 0.56 (95% CrI 0.28 to 1.19, derived ARD 0.56% and NNT 179, I<jats:sup>2<\/jats:sup>=0%). Although the estimated posterior probability of <jats:italic>any<\/jats:italic> benefit was 94.4%, the probability of a <jats:italic>clinically relevant effect<\/jats:italic> was 0\u20130.1% under the vague and informed literature-based priors. Results were robust across multiple sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is a high probability of a beneficial CEP treatment effect, but this is unlikely to be clinically relevant. These findings suggest that future trials should focus on identifying TAVI patients with an increased baseline risk of stroke, and on the development of new generation devices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42023407006.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2023-323359","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T13:20:38Z","timestamp":1700745638000},"page":"757-765","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-6206","authenticated-orcid":false,"given":"Samuel","family":"Heuts","sequence":"first","affiliation":[{"name":"Cardiothoracic Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gabrio","sequence":"additional","affiliation":[{"name":"Methodology and Statistics, Maastricht University, Maastricht, The Netherlands"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Cardiology, Maastricht University Medical Center+, Maastricht, The Netherlands"},{"name":"Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-1450","authenticated-orcid":false,"given":"Bart","family":"Maesen","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kats","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G","family":"Maessen","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony S","family":"Walton","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"Heart Failure Research Group, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Nanayakkara","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"Heart Failure Research Group, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J","family":"Lansky","sequence":"additional","affiliation":[{"name":"Yale Cardiovascular Research Group, Yale Medical School, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W J","family":"van 't Hof","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"},{"name":"Cardiology, Maastricht University Medical Center+, Maastricht, The Netherlands"},{"name":"Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A","family":"Vriesendorp","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands"},{"name":"Cardiology, Maastricht University Medical Center+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2025092014595171000_110.11.757.1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rec.2022.05.006","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European society of cardiology (ESC)","volume":"75","author":"Vahanian","year":"2022","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"2025092014595171000_110.11.757.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923"},{"key":"2025092014595171000_110.11.757.3","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2019.7525","article-title":"Association between transcatheter aortic valve replacement and early postprocedural stroke","volume":"321","author":"Huded","year":"2019","journal-title":"JAMA"},{"key":"2025092014595171000_110.11.757.4","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1161\/CIRCULATIONAHA.120.052874","article-title":"Cerebral embolic protection and outcomes of transcatheter aortic valve replacement: results from the transcatheter valve therapy registry","volume":"143","author":"Butala","year":"2021","journal-title":"Circulation"},{"key":"2025092014595171000_110.11.757.5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2021.01.023","article-title":"Meta-analysis of usefulness of cerebral embolic protection during transcatheter aortic valve implantation","volume":"146","author":"Ahmad","year":"2021","journal-title":"Am J Cardiol"},{"key":"2025092014595171000_110.11.757.6","doi-asserted-by":"crossref","first-page":"101127","DOI":"10.1016\/j.cpcardiol.2022.101127","article-title":"Cerebral embolic protection during transcatheter aortic valve implantation: updated systematic review and meta-analysis","volume":"48","author":"Zahid","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2025092014595171000_110.11.757.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.08.010"},{"key":"2025092014595171000_110.11.757.8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002433","article-title":"Stroke severity is a crucial predictor of outcome: an international prospective validation study","volume":"5","author":"Rost","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2025092014595171000_110.11.757.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa799"},{"key":"2025092014595171000_110.11.757.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs255"},{"key":"2025092014595171000_110.11.757.11","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.4244\/EIJ-D-21-00951","article-title":"Outcomes of stroke events during transcatheter aortic valve implantation","volume":"18","author":"Almarzooq","year":"2022","journal-title":"EuroIntervention"},{"key":"2025092014595171000_110.11.757.12","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann H , Vist G , Higgins J , et al . Interpreting results and drawing conclusions. In: Cochrane Handbook for Systematic Reviews of Interventions, 2nd Edition. The Cochrarne Collaboration, 2019.","DOI":"10.1002\/9781119536604.ch15"},{"key":"2025092014595171000_110.11.757.13","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017496"},{"key":"2025092014595171000_110.11.757.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000173403.60553.27"},{"key":"2025092014595171000_110.11.757.15","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"2025092014595171000_110.11.757.16","first-page":"959","article-title":"Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: a US nationwide study","volume":"98","author":"Khan","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"2025092014595171000_110.11.757.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv191"},{"key":"2025092014595171000_110.11.757.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10302"},{"key":"2025092014595171000_110.11.757.19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4244\/EIJV12I4A84","article-title":"Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial","volume":"12","author":"Van Mieghem","year":"2016","journal-title":"EuroIntervention"},{"key":"2025092014595171000_110.11.757.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.023"},{"key":"2025092014595171000_110.11.757.21","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/eurheartj\/ehab213","article-title":"A randomized evaluation of the TriGuard HDH cerebral embolic protection device to reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial","volume":"42","author":"Lansky","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092014595171000_110.11.757.22","first-page":"515","article-title":"Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II","volume":"14","author":"Nazif","year":"2021","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2025092014595171000_110.11.757.23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa2204961","article-title":"Cerebral embolic protection during transcatheter aortic-valve replacement","volume":"387","author":"Kapadia","year":"2022","journal-title":"N Engl J Med"},{"key":"2025092014595171000_110.11.757.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1408396"},{"key":"2025092014595171000_110.11.757.25","doi-asserted-by":"crossref","unstructured":"Kapadia S , Agarwal S , Miller DC , et al . Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the PARTNER trial. Circ: Cardiovascular Interventions 2016;9. doi:10.1161\/CIRCINTERVENTIONS.115.002981","DOI":"10.1161\/CIRCINTERVENTIONS.115.002981"},{"key":"2025092014595171000_110.11.757.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814052"},{"key":"2025092014595171000_110.11.757.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med"},{"key":"2025092014595171000_110.11.757.28","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4244\/EIJ-D-22-00713","article-title":"Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British heart foundation PROTECT-TAVI trial","volume":"18","author":"Kharbanda","year":"2023","journal-title":"EuroIntervention"},{"key":"2025092014595171000_110.11.757.29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.athoracsur.2018.11.013","article-title":"Development and application of a risk prediction model for in-hospital stroke after transcatheter aortic valve replacement: a report from the society of thoracic surgeons\/American college of cardiology transcatheter valve therapy registry","volume":"107","author":"Thourani","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2025092014595171000_110.11.757.30","doi-asserted-by":"crossref","unstructured":"Reddy RK , Ahmad Y , Arnold AD , et al . Cerebral embolic protection devices during transcatheter aortic valve replacement: a meta-analysis of randomized controlled trials. J Soc Cardiovasc Angiogr Interv 2023;2. doi:10.1016\/j.jscai.2023.101031","DOI":"10.1093\/eurheartj\/ehad655.2217"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2023-323359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:00:00Z","timestamp":1758405600000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2023-323359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/heartjnl-2023-323359"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2023-323359","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}